Achieve Life Sciences (NASDAQ:ACHV) Posts Quarterly Earnings Results, Misses Expectations By $0.06 EPS

Achieve Life Sciences (NASDAQ:ACHV) announced its earnings results on Tuesday. The biopharmaceutical company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.06), Zacks reports.

Achieve Life Sciences Price Performance

Achieve Life Sciences stock opened at $2.65 on Thursday. The stock has a market capitalization of $91.13 million, a price-to-earnings ratio of -2.35 and a beta of 1.67. Achieve Life Sciences has a 52-week low of $2.65 and a 52-week high of $5.59. The stock’s 50 day moving average price is $3.20 and its two-hundred day moving average price is $4.04. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.78 and a current ratio of 6.78.

Analyst Ratings Changes

ACHV has been the topic of several analyst reports. RODMAN&RENSHAW upgraded Achieve Life Sciences to a “strong-buy” rating in a report on Thursday, November 14th. Rodman & Renshaw initiated coverage on Achieve Life Sciences in a report on Thursday, November 14th. They issued a “buy” rating and a $12.00 target price on the stock. Three investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $15.75.

About Achieve Life Sciences

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.